Adverum Biotechnologies has made significant progress in its lead clinical program for intravitreal gene therapy for retinal diseases, Leone Patterson, CEO and president, said at the J.P. Morgan Healthcare Conference.
Real-world anti-VEGF patient outcomes highlight the need for a long-term solution, such as intravitreal gene therapy with ADVM-022, to benefit patients and clinicians.
ADVM-022 is designed to target serious ocular diseases, such as age-related macular degeneration and diabetic retinopathy, with a long-lasting single injection administered in an outpatient setting.
“What we
Uncategorized